Earlier Insight.
Smarter Prevention.
Biomedisca develops point-of-care diagnostic and digital health technologies that help healthcare providers identify risk earlier and support more timely clinical action.
Our flagship product, Medora™, is an investigational fingerstick test designed to identify elevated oral–systemic inflammatory risk during the same clinical visit.
Medora is under development and has not been cleared or approved by the U.S. FDA. It is not currently available for clinical use or sale.
Test ID
MED-ASX-1042-B
Date / Time
Aug 25, 2026 · 14:51
Dual-biomarker analysis in progress
Under 15 Minutes
Designed for same-visit screening.
Fingerstick Sample
Minimally invasive workflow.
Dual-Biomarker Technology
Two complementary inflammatory signals.
Binary Result
Clear screening output.
Oral Inflammation Is Visible.
Systemic Risk May Not Be.
Dentists can identify periodontal disease, but broader inflammation may go undetected. Medora helps assess oral and systemic inflammatory risk during the same visit.
From a Chairside Finding to a More Informed Next Step
Medora is being developed to provide a rapid inflammatory-risk screening result during the dental visit, helping clinicians communicate risk more clearly and consider appropriate medical follow-up when indicated.
Collect a Fingerstick Sample
A small blood sample is collected from the patient at the dental visit.
Prepare the Sample
The sample is prepared and applied to the Medora cassette.
Analyze Two Complementary Signals
The proprietary dual-biomarker technology evaluates the inflammatory-risk signal.
Receive a Binary Result
A clear screening result is available in under 15 minutes.
Discuss Appropriate Follow-Up
The result is reviewed alongside the patient's complete clinical context.
The Medora result is intended to support, not replace, clinician judgment. It does not automatically direct treatment or referral.
Helping Dentistry Participate in Preventive Healthcare
Medora is designed to support the dental office's role in identifying meaningful risk signals earlier.
Same-Visit Insight
Adds an inflammatory-risk signal while the patient is still in the dental office.
Patient Communication
Provides a clear visual result that can support more meaningful oral–systemic health discussions.
Structured Follow-Up
Helps providers consider when medical evaluation may be appropriate.
Longitudinal Monitoring
Designed to support repeat screening and evaluation of inflammatory-risk changes over time.
Preventive Diagnostics Connected to Clinical Intelligence
Biomedisca pairs a point-of-care screening device with supporting digital tools for clearer, more complete clinical information.
Medora™
Medora provides the point-of-care screening signal — an investigational fingerstick test designed to identify elevated oral–systemic inflammatory risk during the dental visit.
Learn about MedoraCORDx
CORDx is being developed to help organize clinical information, preserve clinical reasoning, and support transparent healthcare decisions.
Learn about CORDxMedora and CORDx are distinct products. Medora is the lead diagnostic platform; CORDx is a supporting digital-health layer under development.
Building a Healthier World
We believe the future of healthcare begins before disease becomes severe. Biomedisca is building technologies that connect earlier biological insight with more informed clinical action.
Help Build the Future of Preventive Healthcare
We welcome conversations with clinical investigators, dental practices, medical partners, strategic collaborators, and investors.